Navigation Links
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Date:4/21/2008

Second Phase Opens With Higher Dose Regimens

SAN MARINO, Calif., April 21 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a week for 4 weeks. Treatment cycles are repeated if the patient exhibits Grade 1 or less toxicity. Interim analysis showed no dose limiting toxicities in 9 evaluable patients who received Dose Levels 1-3. Furthermore, the analysis showed decrease in tumor size or disease stabilization (by RECIST), decreased metabolic activity in tumors (by PET-CT scan), reduction in tumor marker levels, and clinical benefit in patients receiving Dose Level 3. The second phase of the Rexin-G study has now opened wherein six patients will receive Dose levels 4 and 5, respectively, as the Phase I/II adaptive study design continues to evaluate the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the clinical benefits required to support a Phase II/III pivotal trial.

*(LOGO: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

According to Dr. Sant P. Chawla, Principal Investigator of the Phase I/II study, "I am happy with the positive results of Rexin-G seen in pancreatic cancer, and look forward to obtaining even better results with progressively higher doses of Rexin-G." Dr. Chawla is currently conducting three Los Angeles-based Phase I/II clinical trials using Rexin-G in sarcoma, pancreatic cancer, and breast cancer, and a Phase II study of Rexin-G for osteosarcoma. For further information concerning these clinical trials, please contact Dr. Erlinda M. Gordon at

SOURCE Epeius Biotechnologies Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
2. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
3. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
10. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014  Mylan Inc. (NASDAQ: MYL ) today ... Abbott (NYSE: ABT ) ... developed markets specialty and branded generics business ("the Assets") in ... will receive 105 million shares of the combined company worth ... on Friday, July 11, 2014, representing an approximately 21% ownership ...
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... component of pharmaceutical marketing and, consequently, organizations are ... specifically for patients. As part of ... learned it,s important to educate, communicate and engage ... from disease awareness to patient empowerment. By mapping ...
(Date:7/11/2014)... Research and Markets  has announced the ... report to their offering. ... a hollow needle commonly used with a syringe to ... fluids from it. A hypodermic needle is used for ... cannot be ingested. Hypodermic needles are broadly classified into ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... spine can happen for any number of reasons, whether it,s ... old age, or blunt injury. Unfortunately, people who have experienced ... back braces, reduced mobility, and elongated periods of pain and ... patients are able to restore proper function to the spine ...
... 17, 2011 Zen Holding Corp. (Symbol: ZNHL) today ... name change to Millennium HealthCare Inc.  The Company will ... change as well. About Zen Holding Corp. ... company that operates thru its wholly-owned subsidiaries Greenleaf Management ...
Cached Medicine Technology:Dr. Seyed M. Rezaian's Spinal Fixator a Revolutionary Invention for Healing Injuries of the Thoracolumbar Spine 2Zen Holding Corp. Changes Name to Millennium HealthCare Inc. 2
(Date:7/14/2014)... 14, 2014 EurekaMag.com has newly published ... is a contagious liver disease that ranges in ... to a serious, lifelong illness that attacks the liver. ... have chronic Hepatitis C virus infection of which approximately ... research category covers all studies on Hepatitis C ...
(Date:7/14/2014)... Wa (PRWEB) July 14, 2014 ... Violet Protocol book review recently updated by ... consists of a wide range of simple ... of endometriosis including:, ... meat and dairy products ,     Increasing ...
(Date:7/14/2014)... 2014 Carepoint has been designed ... by combining an intuitive interface for recording, sending, ... service tracking and reporting features. , Hall mc ... teamed up with Rebecca de Witte to create ... organizations. , Carepoint provides seamless, real-time ...
(Date:7/14/2014)... Columbus, OH (PRWEB) July 14, 2014 ... as litigation continues against seven different pelvic mesh manufacturers ... Virginia notes Wright & Schulte LLC. The federal complaints ... Inc. (MDL No. 2327), American Medical Systems (MDL No. ... of June 16th, there are 58,262 Vaginal Mesh lawsuit ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 In ... carriers emphasized lower-cost narrow-network products, accountable care organizations ... chose coverage based on price, rather than on ... from seeking care from out-of-network providers. “Using ... Narrow Networks and Exchange Products,” the July ...
Breaking Medicine News(10 mins):Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 3Health News:Home Health Care Professional and Marketing Firm Team Up to Create New Homecare Communication App 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:Milliman, FAIR Health Executives to Discuss Data-Based Rate Setting for Out-of-Network Providers in Atlantic Information Services Webinar 2
... drug-eluting stents (DES), could be responsible for causing life-threatening// clots ... Centre has warned. ,Angioplasty is a medical ... or blocked blood vessels of the heart. ... vessel is a common procedure, with over 30,000 cases performed ...
... United States, FDA and Centers for Disease Control are trying ... and peanut butter. Around one hundred cases of salmonella infection ... a group of bacteria that is responsible for causing fever, ... and 600 deaths are reported every year. Generally these infections ...
... effect on weakening of muscles and ligaments in women’s body. ... ,According to Dr. Sandler, the levels of hormones oestrogen and ... When the level of oestrogen decreases during the middle of ... and ligaments and women are prone to back pain during ...
... Organization (PAHO) are working with health authorities in Paraguay ... has affected a// number of communities throughout the nation ... America. ,PAHO officials warn that the entire ... prepare for what promises to be a "difficult year" ...
... cells transplanted into rats’ damaged spinal cords have survived, ... own spinal cord cells in a Johns Hopkins laboratory, ... nerve repair. ,A report on the experiments ... and “establishes a new doctrine for regenerative neuroscience,” says ...
... accurate way to predict the risk of developing cardiovascular ... issue of JAMA. ,"In the decade between ... hypertension (high blood pressure), smoking, diabetes and hyperlipidemia (high ... and coined the term coronary risk factors," according to ...
Cached Medicine News:Health News:PAHO Urges Readiness for Dengue Outbreaks in 2007 2Health News:Human Stem Cell Transplants Repair Rat Spinal Cords 2Health News:New Cardiovascular Risk Prediction Models Developed for Women 2
Full Handle Laseredge Spoon Blade Knife, 3.0 mm angled double bevel. Blade dimension: 11.0 mm (L) x 3.0 mm (W). Cut: 320....
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.2 mm straight. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Full Handle Laseredge Slit Blade Knife, 3.0 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm....
Medicine Products: